In AF and stable CAD, rivaroxaban reduced cardiovascular events and mortality more than rivaroxaban plus an antiplatelet

Gaetano Santulli

Research output: Contribution to journalComment/debate

Original languageEnglish (US)
Pages (from-to)JC6
JournalAnnals of internal medicine
Volume172
Issue number2
DOIs
StatePublished - Jan 21 2020

ASJC Scopus subject areas

  • Internal Medicine

Cite this